OxyContin billionaire is now trying to get you off OxyContin
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
You are now subscribed
Your newsletter sign-up was successful
The man who made billions by selling the highly addictive drug OxyContin has received a patent to sell an opioid treatment.
Richard Sackler, the former chairman and president of the OxyContin maker Purdue Pharma, is one of six inventors listed on a patent "for a new formulation of buprenorphine," Axios reported Friday. The invention is a variation of buprenorphine, a mild opiate that is often used as an OxyContin substitute and a common treatment for opioid addiction, the Financial Times reports. The patent was granted earlier this year.
The inventors could stand to make a lucrative profit from the drug due to the increased need for milder opioid alternatives as the country grapples with a devastating and deadly opioid epidemic. In 2017, British pharmaceuticals group Indivior earned more than $800 million from U.S. sales of buprenorphine, per FT.
Article continues belowThe Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Purdue Pharma, owned by Sackler's family, is currently being sued by more than 1,000 jurisdictions for its involvement in the opioid crisis, Stat reports. The family has denied responsibility.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Marianne is The Week’s Social Media Editor. She is a native Tennessean and recent graduate of Ohio University, where she studied journalism and political science. Marianne has previously written for The Daily Beast, The Crime Report, and The Moroccan Times.
